Pillai N, Liu N, Li X, Li X, Ahrens-Nicklas R, Adang L
Commun Med (Lond). 2025; 5(1):12.
PMID: 39789203
PMC: 11718225.
DOI: 10.1038/s43856-024-00703-8.
Ago Y, Rintz E, Musini K, Ma Z, Tomatsu S
Int J Mol Sci. 2024; 25(2).
PMID: 38256186
PMC: 10816168.
DOI: 10.3390/ijms25021113.
Carvalho S, Santos J, Moreira L, Goncalves M, David H, Matos L
Biomedicines. 2023; 11(4).
PMID: 37189853
PMC: 10135551.
DOI: 10.3390/biomedicines11041234.
Khera G, Chandrika Yelisetty R, Spence G, AlAhbabi W, Dadzie V
Heliyon. 2023; 9(4):e14332.
PMID: 36974319
PMC: 10028354.
DOI: 10.1016/j.heliyon.2023.e14332.
Pierpont E, Isaia A, McCoy E, Brown S, Gupta A, Eisengart J
J Inherit Metab Dis. 2022; 46(2):174-193.
PMID: 36527290
PMC: 10030096.
DOI: 10.1002/jimd.12581.
Early Neonatal Cardiac Phenotype in Hurler Syndrome: Case Report and Literature Review.
Pillai N, Ahmed A, Vanyo T, Whitley C
Genes (Basel). 2022; 13(8).
PMID: 35893030
PMC: 9331972.
DOI: 10.3390/genes13081293.
Quantifying medical manifestations in Hurler syndrome with the infant physical symptom score: associations with long-term physical and adaptive outcomes.
Ahmed A, Rudser K, King K, Eisengart J, Orchard P, Shapiro E
Mol Genet Metab. 2022; 136(1):22-27.
PMID: 35304037
PMC: 9261749.
DOI: 10.1016/j.ymgme.2022.03.003.
Differences in MPS I and MPS II Disease Manifestations.
Hampe C, Yund B, Orchard P, Lund T, Wesley J, McIvor R
Int J Mol Sci. 2021; 22(15).
PMID: 34360653
PMC: 8345985.
DOI: 10.3390/ijms22157888.
Allogenic hematopoietic stem cell transplantation in two siblings with adult metachromatic leukodystrophy and a systematic literature review.
Videbaek C, Stokholm J, Sengelov H, Fjeldborg L, Larsen V, Krarup C
JIMD Rep. 2021; 60(1):96-104.
PMID: 34258145
PMC: 8260480.
DOI: 10.1002/jmd2.12221.
Issues of COVID-19-related distance learning for children with neuronopathic mucopolysaccharidoses.
Eisengart J, Esler A, Ellinwood N, Hudock R, King K, Klein T
Mol Genet Metab. 2021; 134(1-2):68-76.
PMID: 34247933
PMC: 8553302.
DOI: 10.1016/j.ymgme.2021.06.012.
Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies.
Nan H, Park C, Maeng S
Biomed Res Int. 2020; 2020:2408402.
PMID: 33344633
PMC: 7732385.
DOI: 10.1155/2020/2408402.
Induced Pluripotent Stem Cells to Understand Mucopolysaccharidosis. I: Demonstration of a Migration Defect in Neural Precursors.
Lito S, Sidibe A, Ilmjarv S, Burda P, Baumgartner M, Wehrle-Haller B
Cells. 2020; 9(12).
PMID: 33287330
PMC: 7761689.
DOI: 10.3390/cells9122593.
Temporospatial Development of Neuropathologic Findings in a Canine Model of Mucopolysaccharidosis IIIB.
Harm T, Hostetter S, Nenninger A, Valentine B, Ellinwood N, Smith J
Vet Pathol. 2020; 58(1):205-222.
PMID: 33205707
PMC: 8369529.
DOI: 10.1177/0300985820960128.
Gene Therapy Treats Bone Complications of Mucopolysaccharidosis Type II Mouse Models through Bone Remodeling Reactivation.
Wada M, Shimada Y, Iizuka S, Ishii N, Hiraki H, Tachibana T
Mol Ther Methods Clin Dev. 2020; 19:261-274.
PMID: 33102618
PMC: 7567932.
DOI: 10.1016/j.omtm.2020.09.012.
Novel therapies for mucopolysaccharidosis type III.
Yilmaz B, Davison J, Jones S, Baruteau J
J Inherit Metab Dis. 2020; 44(1):129-147.
PMID: 32944950
PMC: 8436764.
DOI: 10.1002/jimd.12316.
Hematopoietic stem cell transplantation in mucopolysaccharidosis type IIIA: A case description and comparison with a genotype-matched control group.
Kohn A, Grigull L, du Moulin M, Kabisch S, Ammer L, Rudolph C
Mol Genet Metab Rep. 2020; 23:100578.
PMID: 32226768
PMC: 7093801.
DOI: 10.1016/j.ymgmr.2020.100578.
Assessment of Activity of Daily Life in Mucopolysaccharidosis Type II Patients with Hematopoietic Stem Cell Transplantation.
Suzuki Y, Taylor M, Orii K, Fukao T, Orii T, Tomatsu S
Diagnostics (Basel). 2020; 10(1).
PMID: 31963134
PMC: 7168225.
DOI: 10.3390/diagnostics10010046.
Genome Editing for Mucopolysaccharidoses.
Poletto E, Baldo G, Gomez-Ospina N
Int J Mol Sci. 2020; 21(2).
PMID: 31941077
PMC: 7014411.
DOI: 10.3390/ijms21020500.
A longitudinal study of neurocognition and behavior in patients with Hurler-Scheie syndrome heterozygous for the L238Q mutation.
Ahmed A, Ou L, Rudser K, Shapiro E, Eisengart J, King K
Mol Genet Metab Rep. 2019; 20:100484.
PMID: 31304092
PMC: 6603334.
DOI: 10.1016/j.ymgmr.2019.100484.
Cell and Gene Therapies for Mucopolysaccharidoses: Base Editing and Therapeutic Delivery to the CNS.
Christensen C, Ashmead R, Choy F
Diseases. 2019; 7(3).
PMID: 31248000
PMC: 6787741.
DOI: 10.3390/diseases7030047.